Drug intelligence / Profile preview

HS-301

Development stage: Discontinued
Lead developer: Hanhui Pharmaceutical
Modality: Small Molecules

Overview

HS-301 is a small-molecule kinase inhibitor developed by Hanhui Pharmaceutical. It was designed to target neurotrophic tyrosine receptor kinase (NTRK) and ROS1 fusion proteins, which are known oncogenic drivers in various solid tumors. By inhibiting these kinases, HS-301 aims to disrupt the signaling pathways that promote tumor growth and survival. However, the development of this compound has reportedly been discontinued.

Targets

ROS1 (Proto-oncogene tyrosine-protein kinase ROS)Trk (Trk receptor family)

Beyond the preview

Go deeper on HS-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-301.

Explore the full profile